Skip to main content

Table 4 Monthly migriane days (MMDs), monthly headache days (MHDs) and HIT6-score (HIT) at M0, M3, M6, M9 and M12 with change from baseline (BL or M0) at M3, M6, M9 and M12

From: One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study

 

M0

M3

M6

M9

M12

Patients (n)

140

140

118

107

102

MHDs

22.5 ± 7.3

14.5 ± 9.6a

13.4 ± 9.0a

12.2 ± 8.6a

11.9 ± 8.7a

 Change from BL

-

8.0 ± 7.1

8.6 ± 7.4

9.4 ± 8.5

9.8 ± 7.8

MMDs

19.6 ± 7.4

11.5 ± 8.5a

10.0 ± 6.8a

9.2 ± 6.1a

9.0 ± 6.3a

 Change from BL

-

8.1 ± 5.9

8.8 ± 6.1

9.1 ± 6.5

9.2 ± 5.7

HIT

68.0 ± 6.0

59.3 ± 8.1a

57.0 ± 8.9a

56.5 ± 9.9a

56.5 ± 9.0a

 Change from BL

-

8.8 ± 7.7

10.9 ± 8.8

11.3 ± 9.6

11.1 ± 8.6

  1. aPaired t-test with M0 < .001